EE9600172A - Puriin-6-ooni derivaadid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja ravimid - Google Patents

Puriin-6-ooni derivaadid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja ravimid

Info

Publication number
EE9600172A
EE9600172A EE9600172A EE9600172A EE9600172A EE 9600172 A EE9600172 A EE 9600172A EE 9600172 A EE9600172 A EE 9600172A EE 9600172 A EE9600172 A EE 9600172A EE 9600172 A EE9600172 A EE 9600172A
Authority
EE
Estonia
Prior art keywords
medicaments
preparation
purin
derivatives
Prior art date
Application number
EE9600172A
Other languages
English (en)
Estonian (et)
Inventor
Niew�Hner Ulrich
Bischoff Erwin
H�ttner Joachim
Perzborn Elisabeth
Sch�tz Helmuth
Original Assignee
Bayer Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Aktiengesellschaft filed Critical Bayer Aktiengesellschaft
Publication of EE9600172A publication Critical patent/EE9600172A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EE9600172A 1995-11-06 1996-11-05 Puriin-6-ooni derivaadid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja ravimid EE9600172A (et)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19541264A DE19541264A1 (de) 1995-11-06 1995-11-06 Purin-6-on-derivate

Publications (1)

Publication Number Publication Date
EE9600172A true EE9600172A (et) 1997-06-16

Family

ID=7776713

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9600172A EE9600172A (et) 1995-11-06 1996-11-05 Puriin-6-ooni derivaadid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja ravimid

Country Status (23)

Country Link
US (1) US5861396A (tr)
EP (1) EP0771799A1 (tr)
JP (1) JPH09124648A (tr)
KR (1) KR970027082A (tr)
AR (1) AR004545A1 (tr)
AU (1) AU720305B2 (tr)
BR (1) BR9605434A (tr)
CA (1) CA2189401A1 (tr)
CO (1) CO4770977A1 (tr)
CZ (1) CZ325096A3 (tr)
DE (1) DE19541264A1 (tr)
EE (1) EE9600172A (tr)
HU (1) HU217691B (tr)
IL (1) IL119559A0 (tr)
MX (1) MX9605371A (tr)
NO (1) NO964667L (tr)
NZ (1) NZ299683A (tr)
PL (1) PL316816A1 (tr)
SG (1) SG64953A1 (tr)
SK (1) SK142596A3 (tr)
TR (1) TR199600883A2 (tr)
TW (1) TW360656B (tr)
ZA (1) ZA969278B (tr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2315736A1 (en) * 1998-01-05 1999-07-15 Eisai Co., Ltd. Purine compounds and adenosine a2 receptor antagonist as preventive or therapeutic for diabetes mellitus
DE19838705A1 (de) 1998-08-26 2000-03-02 Bayer Ag Neue Dihydro-(1,2,3)-triazolo-[4,5-d]pyrimidin-7-one
GB9828340D0 (en) * 1998-12-22 1999-02-17 Novartis Ag Organic compounds
US20040254153A1 (en) * 1999-11-08 2004-12-16 Pfizer Inc Compounds for the treatment of female sexual dysfunction
IL139457A0 (en) 1999-11-08 2001-11-25 Pfizer Compounds for the treatment of female sexual dysfunction
WO2002009713A2 (de) * 2000-08-01 2002-02-07 Bayer Aktiengesellschaft Selektive pde 2-inhibitoren als arzneimittel zur verbesserung der wahrnehmung
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
ATE552013T1 (de) * 2000-09-06 2012-04-15 Mitsubishi Tanabe Pharma Corp Zubereitungen zur oralen anwendung
DE10064105A1 (de) 2000-12-21 2002-06-27 Bayer Ag Neue Substituierte Imidazotriazinone
EP1366760B1 (en) * 2001-02-15 2010-06-30 Mitsubishi Tanabe Pharma Corporation Tablets quickly disintegrated in oral cavity
WO2002068409A1 (en) 2001-02-23 2002-09-06 Merck & Co., Inc. N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
US6479493B1 (en) 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
JP2005508978A (ja) * 2001-11-02 2005-04-07 ファイザー・プロダクツ・インク Ｐｄｅ９阻害薬によるインスリン抵抗性症候群及び２型糖尿病の治療
HRP20050848A2 (en) * 2003-03-04 2006-06-30 Altana Pharma Ag Purin-6-one-derivatives
US20040220186A1 (en) * 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
GB0314054D0 (en) * 2003-06-17 2003-07-23 Pfizer Ltd Amide derivatives as selective serotonin re-uptake inhibitors
US20050054688A1 (en) * 2003-08-08 2005-03-10 Pfizer Inc Selective serotonin reuptake inhibitors in the treatment of disease
JP2007504117A (ja) * 2003-08-28 2007-03-01 アルタナ　ファルマ　アクチエンゲゼルシャフト 肺サーファクタントとｐｄｅ２阻害剤とを含有する組成物
US7291640B2 (en) * 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
ES2313626T3 (es) * 2005-03-21 2009-03-01 Pfizer Limited Derivados de triazol sustituidos como antagonistas de oxitocina.
EP1863484A1 (en) * 2005-03-21 2007-12-12 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
CA2618103A1 (en) * 2005-08-10 2007-02-15 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
EP3091983B1 (en) 2014-01-08 2019-10-02 Intra-Cellular Therapies, Inc. Pharmaceutical compositions comprising a pde-1 inhibitor and a pde-2 inhibitor
AU2015357498B2 (en) 2014-12-06 2019-09-12 Intra-Cellular Therapies, Inc. Organic compounds
US10300064B2 (en) 2014-12-06 2019-05-28 Intra-Cellular Therapies, Inc. Organic compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451478A (en) * 1982-03-12 1984-05-29 Newport Pharmaceuticals International, Inc. Imidazole compounds
IL76546A (en) * 1984-10-12 1988-12-30 Warner Lambert Co 9-(heteroarylalkyl)-6-purine(thi)one derivatives,their preparation and pharmaceutical compositions containing them
US4916225A (en) * 1986-11-25 1990-04-10 Institut Organicheskogo Sinteza Akademii Nauk Latviiskoi Ssr 9-substituted guanines
IT1241452B (it) * 1990-06-28 1994-01-17 Sigma Tau Ind Farmaceuti Derivati oligopeptidici dell'ipoxantina dotati di attivita' immunomodulante e composizioni farmaceutiche che li contengono

Also Published As

Publication number Publication date
DE19541264A1 (de) 1997-05-07
CO4770977A1 (es) 1999-04-30
US5861396A (en) 1999-01-19
SG64953A1 (en) 1999-05-25
TW360656B (en) 1999-06-11
EP0771799A1 (de) 1997-05-07
HUP9603071A3 (en) 1998-04-28
SK142596A3 (en) 1997-05-07
TR199600883A2 (tr) 1997-05-21
HUP9603071A2 (en) 1997-05-28
AU7053296A (en) 1997-05-15
CA2189401A1 (en) 1997-05-07
PL316816A1 (en) 1997-05-12
KR970027082A (ko) 1997-06-24
CZ325096A3 (en) 1997-06-11
BR9605434A (pt) 1998-08-04
HU9603071D0 (en) 1996-12-30
AU720305B2 (en) 2000-05-25
NZ299683A (en) 1998-09-24
NO964667L (no) 1997-05-07
NO964667D0 (no) 1996-11-05
MX9605371A (es) 1997-05-31
ZA969278B (en) 1997-06-02
HU217691B (hu) 2000-03-28
AR004545A1 (es) 1998-12-16
IL119559A0 (en) 1997-02-18
JPH09124648A (ja) 1997-05-13

Similar Documents

Publication Publication Date Title
EE9700145A (et) Tsükloalkaanpüridiinid, nende valmistamismeetod, kasutamine ravimite tootmiseks ja nimetatud ühendeid sisaldavad ravimid
FI955235L (fi) Oksatsolidiinionijohdannaiset, niiden valmistus ja käyttö
FI953479A7 (fi) 1-aryylipyrimidiinijohdannaiset ja niiden farmaseuttinen käyttö
EE03482B1 (et) Kinasoliiniderivaadid, nende valmistamismeetod ja kasutamine
FI934220A7 (fi) Piperidiinijohdannaisia, niiden valmistus ja niiden käyttö terapiassa
FI962927A7 (fi) Tetrasykliinijohdannaisia, valmistusmenetelmä ja käyttö
FI953898A0 (fi) Glysiiniamidijohdannaisia, menetelmiä niiden valmistamiseksi ja niitä sisältäviä lääkeaineita
EE03774B1 (et) 5-O-desosaminüül-6-O-metüülerütronoliid A derivaadid, nende valmistamismeetod ja kasutamine bioaktiivsete produktide valmistamiseks
FI951468L (fi) Lipopeptidijohdannaiset, menetelmä niiden valmistamiseksi ja niiden käyttö
FI944821L (fi) Galantamiinijohdannaisia, menetelmä niiden valmistamiseksi ja niiden käyttö lääkeaineissa
FI955140A7 (fi) Uusia kinoksaliinidionijohdannaisia, niiden valmistus ja käyttö lääkke issä
FI944600L (fi) Imidatsol-4-yylipiperidiinijohdannaisia, niiden valmistus ja niiden käyttö terapiassa
EE200000037A (et) Atsüülpiperasinüülpürimidiinide derivaadid, nende valmistamine ja kasutamine ravimitena
FI944822L (fi) Galantamiinijohdannaisia, menetelmä niiden valmistamiseksi ja niiden käyttö lääkeaineissa
FI944823L (fi) Galantamiinijohdannaisia, menetelmä niiden valmistamiseksi ja niiden käyttö lääkeaineissa
EE9700288A (et) Asatsükloalkaani derivaadid, nende valmistamine ja kasutamine ravis
EE9800145A (et) Fenüülamidiini derivaadid, meetodid nende valmistamiseks ja nende kasutamine arstimitena
EE03878B1 (et) 5-O-desosaminüül-6-O-metüülerütronoliid A derivaadid, nende valmistamismeetod ja kasutamine bioaktiivsete ühendite valmistamiseks
FI941068A7 (fi) Bentsoksatsiinijohdannaiset, niiden valmistus ja terapeuttinen käyttö
EE03687B1 (et) Furaandiarüülmetülideeni derivaadid, nende valmistamise meetod ja kasutamine teraapias
EE200000207A (et) 8-asabitsüklo[3.2.1]oktaan-3-metaanamiini derivaadid, nende valmistamine ja terapeutiline kasutamine
FI970750L (fi) Indoli-2,3-dioni-3-oksimijohdannaisia, niiden valmistus ja käyttö
FI941963L (fi) Pyridiinijohdannaiset, niiden valmistus ja käyttö
FI954141L (fi) Oksatsolokinolonijohdannaiset, niiden valmistus ja niiden käyttö terapiassa
EE9800153A (et) 5-naftalen-1-üül-1,3-dioksaani derivaadid, nende valmistamine ja terapeutiline kasutamine